On Jul. 25, 2025, Simtra BioPharma announced the purchase from Cook Group of a 65-acre property (301 N. Curry Pike) with more than 300,000 square feet of available space for expansion under-roof near its existing manufacturing facility in Bloomington, Indiana.

Leveraging Simtra’s experience and expertise in manufacturing next generation oncology treatments, including ADCs, at its site in Halle/Westfalen, Germany, the addition of this site provides Simtra significant flexibility to rapidly expand its manufacturing footprint in the United States to respond to growing capacity demands from both new and existing customers.

Simtra is evaluating a project to design and install manufacturing lines at the site, including the Company’s first U.S.-based commercial-scale capacity for oncology-focused injectable drug products. The facility would run isolator-based vial and prefilled syringe filling lines. Simtra’s model allows for “build-to-suit” solutions that meet the unique needs of individual customers and their products.

This purchase complements other previously announced investments in the Company’s growth, including the $250 million construction project currently underway at Simtra’s existing Bloomington manufacturing site, and the recently completed $100+ million new production building and $14 million conjugation and purification suite being built in Halle/Westfalen, Germany.

Together, the U.S. and German investments reflect a balanced, global approach to growth, ensuring Simtra can support customers across both continents.